Document:

EX-10.8

 Exhibit 10.8 
 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
 LICENSE AGREEMENT 
 Between 
 INSTITUT PASTEUR, a non profit private foundation organized under the laws of France with offices at 25-28 rue du Docteur Roux, 75 724 Paris Cedex 15, France, VAT FR 65 775 684 897, represented by
M. Christophe Mauriet, Senior Executive Vice-President for Administration, and M. Jean Derégnaucourt, Executive Vice President Business Development 
 Hereinafter referred to as “Institut Pasteur” 
 On one hand, 

And 
 BLUEBIRDBIO INC., a company
incorporated under the laws of Massachusetts, with offices at 840 Memorial Drive, Cambridge, MA 02139, United States, represented by Nick Leschly, Chief Executive Officer 
 Hereinafter referred to as “Licensee”, 
 On the other hand, 

Hereinafter mentioned as a Party or the Parties. 
 Recitals 
 1. Institut Pasteur has identified and patented a specific nucleotide sequence
having a triplex structure, hereinafter referred to as “DNA flap”, covered by patents and patent applications. 
 2. Institut Pasteur
has granted several exclusive or non exclusive licenses on the DNA flap under several fields to companies. 
 3. Licensee is a company
developing innovative gene therapies for severe genetic disorders. 
 4. Licensee wishes to obtain a license of such patents and commercialize
products for gene therapy. 
 5. Licensee and Institut Pasteur have decided to discuss terms of a license agreement according to the terms and
conditions of this Agreement. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 Now, therefore, the Parties hereby agree as follow: 

Article 1. Definitions 
 For the purpose
of this Agreement, the terms used in this Agreement, in singular or in plural, shall have the respective meanings set forth below: 
  

	 	•	 	 “Affiliate” means with respect to Licensee any party which (directly or indirectly) is controlled by, controls, or is under common
control with, Licensee. For the purposes of this definition, the terms “control” and “controlled” mean the direct or indirect ownership of more than fifty percent (50%) of the outstanding voting securities of an entity, or
such other relationship as results in actual control over the management, assets, business and affairs of such entity. 

  

	 	•	 	 “Agreement” shall mean this license agreement together with its appendices which make integral part of it. 

 

	 	•	 	 “Confidential Information” shall mean any and all confidential information, whatever its nature or its format, which is disclosed by one
Party to the other Party hereunder and that is marked confidential or with similar term, if disclosed in writing, or if disclosed orally, identified as confidential at the time of disclosure. Notwithstanding the foregoing, any information which, by
its nature and under the circumstances surrounding its disclosure is generally considered proprietary and confidential shall be deemed Confidential Information regardless of whether it is properly marked with legends or properly reduced to writing.

  

	 	•	 	 “Development Plan” shall mean a document defining the research and development of the Licensee and/or Affiliates as well as the commercial
and financial development estimates of Licensee and/or Affiliates for its Product(s) using the Technology in the Field. 

  

	 	•	 	 “Effective Date” shall mean the date of the last signature of this Agreement by the Parties. 

 

	 	•	 	 “Ex vivo gene therapy” shall mean that cells are extracted from a patient, corrected by placing a healthy or functional gene(s) and
transplanted back into patient. 

  

	 	•	 	 “Field” shall mean ex vivo gene therapy for human disorders limited to adrenoleukodystophy (ALD) (including but not limited to AMN, CCALD,
and all other variants of this disease caused by genetic mutations), beta hemoglobinopathies (including but not limited to beta-thalassemia and sickle cell anemia), [***], the “Field” includes in vivo as well as ex vivo gene therapy.
Licensee and/or Affiliates shall have the right to request Institut Pasteur to expand the definition of “Field” to include additional clinical areas. [***] For clarity, the Field excludes any other fields and specifically prophylactic and
therapeutic human and veterinary vaccination against all kind of pathogens, and the field of services of production and commercialisation of Good Manufacturing Practice (GMP) batches of lentiviral vectors for clinical trials. For clarity, the Field
shall include production of GMP batches, by Licensee and its Affiliates [***]. For clarity, Institut Pasteur has already granted exclusive rights for services of production and commercialisation of Good Manufacturing Practice (GMP) batches of
lentiviral vectors for clinical trials. [***] 

  

	 	•	 	 “Improvement” shall mean any new invention, patentable or not, patented or not, of the Technology, which under applicable law, depends on, at
least, one claim of the Patents. For clarity, an Improvement does not include any Product. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

	 	•	 	 “Net Sales” shall mean the gross amount, excluded taxes, invoiced for sale of Products manufactured or sold in the Territory, in finish or
semi finish form by Licensee and/or Affiliates less the following items, consistent with U.S. GAAP: 

  

	 	a)	trade, quantity and cash discounts actually allowed; 

  

	 	b)	commissions, discounts, refunds, rebates, charge backs, retroactive price adjustments, and any other allowances paid to non-governmental Third Parties that effectively
reduce net selling price; 

  

	 	c)	credits, allowances and refunds for actual Product rejections, returns and allowances; 

 

	 	d)	taxes, duties and other governmental charges on the sale, shipment or transfer of the Product; and 

 

	 	e)	duly justified governmental discounts, refunds, rebates, charge backs, retroactive price adjustments and any other allowances that effectively reduce net selling price.

 It is understood that deductions set forth in a), b) and c) herein above shall not exceed [***] of gross
revenue, excluded taxes, invoiced for sale of Products in the Territory. 
  

	 	•	 	 “Patents” shall mean the patents and patents applications listed in Appendix 1, along with all other patent rights (including but not limited
to continuations, continuations-in-part (but only for those claims of such continuations-in-part that are fully supported by the patents and patent applications listed in Appendix 1 as of the Effective Date), divisionals, renewals, reissues,
re-examinations, patent term extensions) that claim priority in whole or in part to any such patents and patent applications. 

  

	 	•	 	 “Product” shall mean all composition or product for gene therapy or method in the Field that incorporate the Technology.

  

	 	•	 	 “Rare Diseases” shall include adrenoleukodystophy (ALD) (including but not limited to AMN, CCALD, and all other variants of this disease
caused by genetic mutations), beta hemoglobinopathies (including but not limited to beta-thalassemia and sickle cell anemia), [***]. Whether in the case of [***], such diseases shall be considered on a case-by-case basis and considered a Rare
Diseases if the incidence or prevalence is similar to those diseases listed as Rare Diseases above. In these situations, Licensee and/or Affiliates shall provide justification as to whether such disease is a Rare Disease, in writing, prior to
payment of the Milestone #4 or #5 as applicable. 

  

	 	•	 	 “Technology” shall mean lentivirus vector containing DNA flap sequence covered by whole or part of the claims of the Patents.

  

	 	•	 	 “Territory” shall mean all countries of the world, regarded together as a single indivisible territory. 

 

	 	•	 	 “Third Party” shall mean any party which is not Institut Pasteur or Licensee or its Affiliates. 

Article 2. Scope 
 2.1. Under this
Agreement, Institut Pasteur grants to Licensee and its Affiliates, that Licensee and its Affiliates accepts at their own risks, a license under the Patents in the Field and in the Territory for research and development, and to manufacture, have
manufactured, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import or have imported the Products, to the exclusion of any other rights, which is: 

 

	 	•	 	 exclusive for Products containing human (HIV-1 and HIV-2) lentivirus vector, and ; 

 

	 	•	 	 non exclusive for Products containing non-human lentivirus vector. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 2.2. No right granted herein shall prevent Institut Pasteur or its licensees or research partners to
conduct research in the Field. 
 2.3. This Agreement includes the right for Licensee and/or Affiliates to grant sublicenses in the Field and
the Territory to and through multiple tier(s) of Third Party(ies). 
 Article 3. Licensee’s obligation 

3.1. Licensee shall make, or shall cause its Affiliates and sublicensee to make, all reasonable commercial efforts (by reference to a company of similar
size and scope to Licensee as of the Effective Date) to develop and commercialize one or more Products in the Field and to obtain any necessary governmental approvals in respect of, and market the Product(s) in the Field, if any. It is expressly
agreed that fulfillment of the above obligation is an absolute requirement for this Agreement to be maintained into force. 
 3.2. Licensee
shall provide annually, upon each anniversary date of the Effective Date, to Institut Pasteur an updated Development Plan, which will be Confidential Information of Licensee. [***] 
 3.3. Licensee is the sole responsible for securing the compliance of Products with applicable laws, rules and regulations, in particular, but without limitation, such as relating to ethics, the treatment
of animals, and genetically modified organisms, if any. 
 Article 4. Intellectual property 

4.1. The provisions of this Agreement shall not modify the ownership of the Technology and Patents. 

4.2. Any Improvement of the Technology made without Institut Pasteur by the Licensee shall belong to Licensee. 

4.3. Any Improvement of the Technology made with the help of Institut Pasteur will be co-owned by Institut Pasteur and Licensee. A specific agreement
shall be established between the co-owners within six (6) months following the identification of the joint Improvement. 
 4.4. Upon
request of Institut Pasteur, Institut Pasteur and Licensee agrees to meet in view to determine the conditions under which Licensee shall grant Institut Pasteur, a non exclusive, free license on the Improvement if possible and available mentioned in
articles 4.2 and 4.3 above, for internal research purpose. Licensee and/or Affiliates shall ask to Institut Pasteur to submit a supplementary protection certificate (SPC) for any Product. To this aim, Licensee shall provide Institut Pasteur all
necessary information. This SPC shall automatically be part of the Agreement. 
 4.5. From the Effective Date, Licensee shall pay to Institut
Pasteur [***] of future external expenses engaged by Institut Pasteur for securing issuance of, and maintaining Patents or extending the duration of the Patents. Institut Pasteur shall not abandon any Patent without the prior notice of Licensee.

 4.6. Upon written request, but at most once a year, Institut Pasteur shall keep Licensee informed of the status of issuance procedures of
Patents, and shall update Appendix 1 accordingly. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 4.7. Licensee acknowledges that Institut Pasteur has expended significant resources and efforts to
develop the Patents, and that the Patents represents highly valuable interests, and agrees not to take any action to jeopardize, limit or interfere in any manner with Institut Pasteur’s ownership and intellectual property rights with respect to
the Patents. 
 4.8. In the case a Patent is challenged (including but not limited to a re-examination, opposition or interference proceeding,
but not including when part of an infringement action described above), the Parties shall make available to the other all information they have, and shall meet to decide the defense strategy. [***] 

Article 5. Infringement 
 5.1. Institut
Pasteur and Licensee shall as soon as they become aware thereof mutually advise each other of any infringement of Patents by a Third Party in the Field. Institut Pasteur and Licensee shall make available to the other all information at their
disposal on the basis of which nature and extend can be assessed. 
 5.2. [***] 
 5.3. In the case Licensee is sued by a Third Party regarding Technology in a Product, the Parties shall make available to the other all information they have, and shall meet to decide the defense
strategy, if any, with respect to such Technology. 
 Article 6. Consideration 
 6.1. Within thirty (30) days of the Effective Date, Licensee shall pay to Institut Pasteur a one-time, non-refundable license issuance fee [***] exclusive of taxes. This amount cannot be set-off
against future royalties. 
 6.2. For the development of each Product indication by indication, except in the case mentioned below, Licensee
and/or Affiliates shall pay to Institut Pasteur the following milestones: 
  

									
	 	  	[***]	  	[***]	  	[***]	  	[***]
	 Milestone 1: [***]
	  	[***]	  	[***]	  	[***]	  	[***]
	 Milestone 2: [***]
	  	[***]	  	[***]	  	[***]	  	[***]
	 Milestone 3: [***]
	  	[***]	  	[***]	  	[***]	  	[***]
	 Milestone 4: [***]
	  	[***]	  	[***]	  	[***]	  	[***]
	 Milestone 5: [***]
	  	[***]	  	[***]	  	[***]	  	[***]
	 Milestone 6: [***]
	  	[***]	  	[***]	  	[***]	  	[***]

 For the foregoing table: 
  

	 	•	 	 [***] 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

	 	•	 	 For each Product (including multiple indications for the same Product), only one column is applied and each milestone in such column is paid only once
at the first occurrence of such event 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

 For further
clarity, with respect to the second tabbed paragraph above, if the same Product is developed or approved for more than one indication, the specified milestones for a column shall be paid one time only at the first occurrence of such event. As a
specific example, [***]. 
 6.3. Until the expiration of the last Patent claiming a Product in the Territory, Licensee and/or Affiliates shall
pay to Institut Pasteur the following yearly royalty fees: 
  

	 	•	 	 [***] of Net Sales for a Product with an indication in a Rare Disease, without stacking clause, and 

 

	 	•	 	 [***] of Net Sales for a Product with an indication in a disease other than a Rare Disease, without stacking clause; 

[***]. 
 6.4. If the combined
royalties Licensee and/or Affiliates would be required to pay to Institut Pasteur and Third Parties, is higher than [***] for one Product, Licensee and/or Affiliates may ask Institut Pasteur to negotiate the royalty fees of the article 6.3.

 6.5. Licensee and/or Affiliates shall pay to Institut Pasteur a minimum annual fee [***] exclusive of taxes per twelve (12) month period
and due at the end of such period which shall start from the fifth anniversary of the Effective Date of this Agreement for all Products. For clarity, such payment shall be offset by the royalties payments made to Institut Pasteur during such 12
month period. If no Product is on the market after the fifth anniversary of the Effective Date, this minimum annual fee shall be reduced [***] exclusive of taxes until the first Product shall be on the market, date on which the minimum annual fee
shall be again [***] exclusive of taxes per twelve (12) month period. 
 6.6. Licensee and/or Affiliates shall pay to Institut Pasteur
[***] of all cash and cash-equivalent consideration, whatever its nature, and in particular without limitation, all sums, milestones, royalties, exchange value of any counterpart in kind or in industry (but not duly justified payments for research
and development) received by Licensee and/or Affiliates from its all sublicenses agreements granted by Licensee and/or Affiliates on the sole Technology. 
 6.7. On a indication-by-indication basis, in case of sublicenses relating to a Product, Licensee and/or Affiliates shall pay to Institut Pasteur on any and all cash and cash-equivalent consideration,
whatever its nature, and in particular without limitation, all sums, milestones, royalties, exchange value of any counterpart in kind or in industry (but not duly justified payments for research and development) received by Licensee and/or
Affiliates from a sublicensee: 
  

	 	•	 	 [***] if the sublicense is signed for Product(s) in a preclinical stage development, or, 

 

	 	•	 	 [***] if the sublicense is signed for Product(s) in a clinical stage of development. 

6.8. If the combined royalties Licensee and/or Affiliates would be required to pay to Institut Pasteur and Third Parties, is higher than [***] for one
Product, Licensee and/or Affiliates may ask Institut Pasteur to negotiate the royalty fees of the article 6.7. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 6.9. Notwithstanding the foregoing, in the case of a sublicense of the Technology for a Product for ALD
(including but not limited to AMN, CCALD, and all other variants of this disease caused by genetic mutations), beta-thalassemia and/or sickle cell anemia, Institut Pasteur shall receive the same Milestones and Royalties as if Licensee and/or
Affiliates itself were developing and commercializing such Product(s) (and thus no amounts shall be payable to Institut Pasteur under Article 6.7). Licensee and/or Affiliates shall be liable for ensuring such payment in accordance with the terms of
this Agreement. 
 Article 7. Payment 
 7.1. Payment of royalties due under this Agreement shall be made within forty-five (45) days from the invoice date, after the end of each six-month period’s Net Sales (ending 30 June and 31
December) for the sum corresponding to that period. 
 7.2. Any payment due by Licensee, pursuant to this Agreement, shall be made in euros by
check or by wire transfer to a bank account as designated by Institut Pasteur from time to time. 
 7.3. Royalties arising out of Net Sales
achieved in currencies other than the Euro shall be converted at the current average exchange rate one month prior to the date upon which the royalties report is due, and shall be borne by Licensee. 

7.4. Notwithstanding the provisions of this Agreement, sums paid to Institut Pasteur shall in any event be retained by Institut Pasteur. Any VAT (Value
Added Tax) due, if any, shall be added to the invoiced amount at the then current rate, and shall be borne by Licensee. 
 7.5. Any withholding
tax payable by Licensee on royalties due hereunder shall be deducted from royalties due for the relevant country. Licensee shall be responsible for obtaining and providing to Institut Pasteur evidence of the payment of such withholding taxes.
Licensee shall assist Institut Pasteur to prevent any double taxation and shall provide Institut Pasteur on request with any document necessary to that end. 
 7.6. The royalties and other payments set forth in this Agreement shall, if overdue, bear interest until paid at a per annum rate of [***]. The payment of such interest shall not foreclose Institut
Pasteur from exercising any other rights or actions it may have as a consequence of the lateness of any payment. 
 Article 8. Accounts

 8.1. Licensee shall simultaneously with payments of royalties deliver to Institut Pasteur a report reflecting its accounts and
sub-licenses accounts, pertaining to royalties calculated, on Net Sales, including: 
  

	 	•	 	 [***]; 

  

	 	•	 	 [***]; and 

  

	 	•	 	 [***]. 

 Such report maybe
delivered by email to the following email address (which address may be updated by written notice from Institut Pasteur to Licensee): Service de Transfert de Technologie, [***]. 
 8.2. When no royalty is payable, a report so attesting shall be submitted to Institut Pasteur. The aforesaid reports shall be treated as Confidential Information of Licensee. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 Such report maybe delivered by email to the following email address (which address may be updated by
written notice from Institut Pasteur to Licensee): Service de Transfert de Technologie, [***]. 
 8.3. Licensee shall keep complete and accurate
records of all Net Sales, allowing a computation and checking of the royalty amount due to Institut Pasteur hereunder. Once a year and upon prior notice to Licensee and/or Affiliates, Institut Pasteur shall, throughout the term of this Agreement,
and for a period of three (3) years following the end of this Agreement, be entitled to have at its own expense and during regular business hours Licensee’s records pertaining to this Agreement checked by an independent certified public
accountant chosen by Institut Pasteur and reasonably acceptable to Licensee, which accountant shall enter into a confidentiality agreement with Licensee. Such accountant shall be appointed for the sole purpose of determining the amount of royalties
due to Institut Pasteur hereunder, covering a period not to exceed the past three (3) years, provided that [***] such accountant shall report to Institut Pasteur only as to the accuracy of royalty statements and payments and that such reported
information shall be considered to be Confidential Information of Licensee. 
 8.4. If, as a result of such audit, an adjustment is determined
to be made in favor of Institut Pasteur, the accountant’s fees and expenses shall be borne by Licensee, if the sums underpaid by Licensee exceed [***] of what was actually paid by Licensee to Institut Pasteur; otherwise such fees and expenses
shall be paid by Institut Pasteur. Licensee shall pay any underpaid royalties to Institut Pasteur. 
 Article 9. Confidentiality

 9.1. Confidential Information does not include information for which it is evidenced that: 

 

	 	•	 	 is publicly known and made generally available in the public domain prior to the time of disclosure by the providing Party,

  

	 	•	 	 becomes publicly known and made generally available after disclosure by the providing Party to the receiving Party through no action or inaction of the
receiving Party, 

  

	 	•	 	 is already in the possession of the receiving Party at the time of disclosure by the providing Party as shown by the receiving Party’s documentary
evidence, 

  

	 	•	 	 is obtained by the receiving Party from a Third Party without breach of such Third Party’s obligations of confidentiality, as shown by the
receiving Party’s documentary evidence, 

  

	 	•	 	 is required by law to be disclosed by the receiving Party. 

 9.2. In the event that the receiving Party is notified of a requirement to disclose the providing Party’s Confidential Information, the receiving Party shall notify the providing Party immediately
upon receipt of such notice and not release the Confidential Information until such time as the providing Party has taken reasonable steps to seek an order of a court of competent jurisdiction to prevent the disclosure, or limit the extent of
disclosure, of the providing Party’s Confidential Information. 
 9.3. During the term of this Agreement and five (5) years
thereafter, the receiving Party agrees to keep confidential and cause its employees, consultants or students to keep confidential, all Confidential Information of the providing Party that is disclosed to it, or to any of its employees, consultants
or students under or in connection with this Agreement. 
 9.4. Neither the receiving Party nor any of its respective employees, consultants or
students, shall use Confidential Information for any other purpose whatsoever except as expressly permitted by this Agreement. 
 9.5. The
receiving Party may not disclose providing Party’s Confidential Information to a Third Party without the prior written consent of the providing Party, other than for Licensee and/or Affiliates in connection with a proposed or actual sublicense
or transaction permitted by Article 13.7 or for other reasonable business purposes, subject to the confidentiality protections stated above, for the purpose of this Agreement. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 9.6. Following expiration or termination of this Agreement, the receiving Party shall return all the
Confidential Information to the providing Party, or destroy such Confidential Information at the providing Party request, with the exception that (1) one copy of the Confidential Information that may be retained by the receiving Party’s
legal counsel for the purpose of verifying its obligations under this Agreement. 
 Article 10. Representations and Warranties

 10.1. At the Effective Date, each Party represents and warrants to the other Party that it has the right to enter into this Agreement.

 10.2. Licensee agrees that all Confidential Information or any other information or data communicated or provided by Institut Pasteur under
this Agreement are communicated “as is”, without any warranty, expressed or implied, regarding accuracy, completeness, merchantability, fitness, patentability and/or performance. Any hazards, costs and risks that may be incurred by
Licensee in connection with the use of all or part of the Products, resulting, in particular, from possible defects or from the eviction risk, are the sole responsibility of Licensee. Institut Pasteur shall not be liable for any consequential,
indirect or punitive damages or lost profits of Licensee. 
 10.3. Institut Pasteur gives no warranty whatsoever express or implied, in respect
of the Patents, in particular as regards of its usefulness, safety or fitness for a particular purpose. Institut Pasteur does not, either expressly or tacitly warrant that the use of the Patents granted under this Agreement shall allow the
production of Product, as well as the manufacture, sale, use, importation, exportation and holding of Products shall not infringe a Third Party’s intellectual proprietary rights or violate any rights in particular license rights, already
granted to a Third Party. Licensee undertakes not to enforce any remedy, including a claim under any guarantee against Institut Pasteur, for compensation of whatever damage which might arise out of or in connection with the use or non use of the
Patents. 
 10.4. Nothing in the Agreement shall be construed as: (a) a warranty or representation by Institut Pasteur as to the validity
or scope of any Patents; (b) a warranty or representation by Institut Pasteur that the practice under the Patents is or will be free from infringement of patents of any Third Party or rights granted to Third Party; (c) except as expressly
set forth herein, an obligation to Institut Pasteur to sue Third Party for infringement; or (d) conferring by implication, estoppels or otherwise any license, immunity or right under any patent owned by or licensed to Institut Pasteur other
than the Patents. 
 10.5. Institut Pasteur shall under no circumstances be held liable to Licensee, whether expressly or impliedly, for any
direct, indirect, consequential or special damages in relation to the use or sale of Patents and/or Products by Licensee. Licensee shall indemnify and hold Institut Pasteur harmless from all costs and expenses of any kind, arising from or resulting
of any Third Party claim against Institut Pasteur relating to the use, handling or storage by Licensee of the Patents or Confidential Information, as well as the manufacture, sale, use, importation, exportation and holding of Product, except where
such claims arise from a finding of gross negligence or willful misconduct by Institut Pasteur only with respect to the Patents or Confidential Information, to the exclusion of Products. [***] 

10.6. Institut Pasteur may terminate this Agreement with immediate effect in the event that Licensee, either directly or indirectly, or its Affiliates
challenges the validity of any of the Patents. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 Article 11. Term and Termination 
 11.1. This Agreement shall be effective from the Effective Date. 
 11.2. Unless sooner terminated
under the articles below, this Agreement shall be effective until the last Patents to expire in the Territory. 
 11.3. This Agreement may be
terminated without any indemnification, by either Party at any time during this Agreement if the other Party is in substantial breach of its obligations hereunder and has not cured such breach within sixty (60) days after a registered letter
notifying such substantial breach, without prejudice of any right to pursue an action for damages as a result of such breach. 
 11.4. Institut
Pasteur may also terminate this Agreement without fault where collective proceedings – bankruptcy, suspension of proceedings – are opened against Licensee and not dismissed within sixty (60) days thereafter. 

11.5. Licensee may terminate this Agreement by a written notice sent ninety (90) days in advance. 

11.6. Termination of this Agreement for any reason shall not affect each Party’s continuing obligations to the other Party under this Agreement or
pursuing provisions. Upon termination of this Agreement, as long as there are always unexpired Patents under the Territory, this license shall automatically terminate and Licensee shall promptly cease any use of the Patents and shall cease
manufacturing, importing, using and selling Products within [***] form the effective date of the termination. 
 11.7. Upon termination of this
Agreement, Institut Pasteur shall have the right to retain any sums already paid by Licensee hereunder, and Licensee shall pay all sums accrued hereunder which are then due, including all sums generated during the three month period mentioned in
Article 11.6 of this Agreement. 
 11.8. Articles 1, 3.3, 4.1 to 4.3, 7 to 10, 11.6, 11.7, 11.8 and 12 shall survive any termination or
expiration of this Agreement. 
 Article 12. Litigation and governing law 
 12.1. This Agreement shall be construed and governed by the Laws of France. The language of this Agreement shall be English. 
 12.2. The Parties shall attempt to settle any dispute relating to this Agreement, its validity and/or its interpretation and/or its enforceability and/or its termination, in an amicable way. Should such
attempts fails, the litigation will be held in the court of the competent jurisdiction in France. 
 Article 13. Miscellaneous

 13.1. This Agreement contains the entire understanding and agreement between the Parties hereto with respect to its subject matter, and
except where otherwise provided herein, supersedes any prior or contemporaneous written or oral agreement between them relating to the subject matter hereof. 
 13.2. The Parties agree to keep the existence and the terms and conditions of this Agreement strictly confidential, and shall not disclose the existence and the terms and conditions of this Agreement to
any Third 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 
Party, except as required by law (including but not limited to in connection with a public securities offering) or by Licensee in connection with a proposed or actual sublicense or transaction
permitted by Article 13.7 or for other reasonable business purposes. Moreover, nothing contained in this Agreement shall grant to Licensee a right to use for advertising, publicity or any promotional activity whatsoever Institut Pasteur’s
names, trademarks, logo or any other designations, including in contracted or abbreviated form or by imitation, subject to a prior express written consent of Institut Pasteur. Notwithstanding the foregoing, Licensee may disclose the existence of
this Agreement and the fact that Institut Pasteur has granted an exclusive license under the Patents to Licensee. 
 13.3. This Agreement may be
amended only by a written amendment signed by the Parties. 
 13.4. If any term, provision or condition of this Agreement shall be held by a
court of competent jurisdiction to be invalid, unenforceable or void, the remainder of this Agreement shall remain in full force and effect. 

13.5. Any notice required or permitted to be given under this Agreement shall be sufficient if sent by commercial courier or certified mail (return
receipt requested), facsimile, or postage prepaid, addressed to the address mentioned in first page of this Agreement. 
 13.6. Neither Party
shall be liable to the other for any default under this Agreement caused by war, riot, fire, flood, drought, act of God or any other cause which is beyond the reasonable control of the defaulting Party, as acknowledged by the court of competent
jurisdiction. 
 13.7. This Agreement being entered into for the benefit of consideration of the Parties, shall not be assigned or transferred,
whether in whole or in part, without the other Party’s prior written consent; provided that Licensee may assign this Agreement to an Affiliate or in connection with the merger, consolidation, or sale of all or substantially all of its assets or
that portion of its business pertaining to the subject matter of this Agreement, and the assignee shall notify Institut Pasteur of such assignment and shall agree in writing to be bound to the terms of this Agreement as “Licensee”
hereunder. 
 13.8. The relationship created by this Agreement shall be that of independent contractors. 

13.9. The failure or neglect of a Party at any time, to require performance of the other Party of any provision hereof, shall not in any way affect the
right to require such performance at any time thereafter. The waiver by a Party of any breach of any provision hereof shall not be held to be a waiver of any subsequent breach of the same provision or of any other provisions hereof. 

[remainder of this page intentionally left blank] 

  
 CERTAIN CONFIDENTIAL PORTIONS
OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their authorized respective
representative. 
 Made in Paris, 
 In
duplicate. 
  

					
	 Date: 08 SEP. 2011
  

/s/ Christophe Mauriet
	 		 	 Date: 13-Sept 2011
  

/s/ Nick Leschly

	 INSTITUT PASTEUR
 Christophe
Mauriet
 Senior Executive Vice-President
	 		 	 BLUEBIRDBIO INC.
 Nick
Leschly
 Chief Executive Officer

			
	 Date: 26/8/11
  

/s/ Jean Derégnaucourt
 INSTITUT PASTEUR
 Jean Derégnaucourt
 Executive Vice-President Business Development
	 		 	

  
 CERTAIN CONFIDENTIAL PORTIONS
OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

 Appendix 1 
 Patents 
  

					
	 Invention
	  	Priority/Filing
date
Extension/Filing date	  	Territories / Filing date
Legal 
Status
	 [***]
	  		  	

 Institut Pasteur hereby confirms that the foregoing is a complete and accurate list of all the Patents as the Date of
August 11,2011. 

  
 CERTAIN CONFIDENTIAL PORTIONS
OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

 AMENDMENT N°1 TO THE LICENSE AGREEMENT 

Between 
 INSTITUT PASTEUR, a non profit
private foundation organized under the laws of France with offices at 25-28 rue du Docteur Roux, 75 724 Paris Cedex 15, France, VAT FR 65 775 684 897, represented by M. Christophe Mauriet, Senior Executive Vice-President for Administration

 Hereinafter referred to as “Institut Pasteur” 
 On one hand, 
 And 
 BLUEBIRDBIO INC., a company incorporated under the laws of Massachusetts, with offices at 840 Memorial Drive, Cambridge, MA 02139, United States, represented by Nick Leschly, Chief Executive
Officer 
 Hereinafter referred to as “Licensee”, 
 On the other hand, 
 Hereinafter mentioned as a Party or the Parties. 

Recitals 
 1. The Parties have signed a
license agreement on September 13, 2011 on a patented specific nucleotide sequence having a triplex structure, referred to as “DNA flap”. 
 2. Institut Pasteur has granted several exclusive or non exclusive licenses on the DNA flap under several fields to companies, [***]. 
 3. Institut Pasteur has negotiated with a licensee to obtain rights for the Licensee in this field of services of production and commercialization of Good Manufacturing Practice (GMP) batches of
lentiviral vectors for clinical trials, according to the terms and conditions of this Amendment n°1. 

  
 CERTAIN CONFIDENTIAL PORTIONS
OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

 Now, therefore, the Parties hereby agree as follow: 

Article 1. Scope 
 The scope of this
Amendment n°1 is to extend the Field of the Agreement and the license grants by Institut Pasteur. 
 Article 2. Modifications

 2.1. The definition of the Field in the article 1 of the Agreement is replaced by the following definition as from the effective date of
this Amendment n°1: 
  

	 	•	 	 “Field” shall mean ex vivo gene therapy for human disorders limited to adrenoleukodystophy (ALD) (including but not limited to AMN, CCALD,
and all other variants of this disease caused by genetic mutations), beta hemoglobinopathies (including but not limited to beta-thalassemia and sickle cell anemia), [***] for [***] the “Field” includes in vivo as well as ex vivo gene
therapy. [***] 

 2.2. The article 2.1 of the Agreement is modified as follow, as from the effective date of this Amendment
n°1: 
 “2.1. Institut Pasteur hereby grants to Licensee, its Affiliates, that Licensee, its Affiliates accept at their own risk, a
license under the Patents in the Field and in the Territory for research and development, and to manufacture, have manufactured, make, have made, use, have used, sell, have sold, offer for sale, have offered for sale, import or have imported the
Products, to the exclusion of any other rights, the said license being: 
  

	 	•	 	 exclusive for Products containing human (HIV-1 and HIV-2) lentivirus vector; 

 

	 	•	 	 nonexclusive for Products containing non-human lentivirus vector. 

 In addition, Institut Pasteur hereby grants to Licensee, its Affiliates and sublicensees, that Licensee, its Affiliates and sublicensees accept at their own risk, a nonexclusive license under the Patents
in the Field and in the Territory to make or to have made by a Thirty Party Good Manufacturing Practice (GMP) batches of lentiviral vectors for its/their own clinical trials on Products, provided that such Third Party makes Good Manufacturing
Practice (GMP) batches of lentiviral vectors solely for the Licensee, its Affiliates and sublicensees clinical trials of Products above mentioned. 
 2.3. The article 10.5 of the Agreement is modified as follow, as from the effective date of this Amendment n° l: the last sentence of such article 10.5 is modified as follow: [***] 

Article 3. Miscellaneous 
 3.1. All the
other provisions of the Agreement remain unchanged and fully applicable between the Parties. 
 3.2. This Amendment n°1 is effective from
the date of signature by the Parties. 
 3.3. This Amendment n°1 makes integral part of the Agreement. 

  
 CERTAIN CONFIDENTIAL PORTIONS
OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT
PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
  

 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their authorized respective
representative. 
 Made in Paris, 
 In
duplicate. 
  

					
	 Date: 27 AVR. 2012
  

/s/ Christophe Mauriet
	 		 	 Date:
  

/s/ Nick Leschly

	 INSTITUT PASTEUR
 Christophe
Mauriet
 Senior Executive Vice-President
	 		 	 BLUEBIRDBIO INC.
 Nick
Leschly
 Chief Executive Officer

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 AMENDMENT N°2 TO THE LICENSE AGREEMENT 

Between 
 INSTITUT PASTEUR, a non profit
private foundation organized under the laws of France with offices at 25-28 rue du Docteur Roux, 75 724 Paris Cedex 15, France, VAT FR 65 775 684 897, represented by M. Christophe Mauriet, Senior Executive Vice-President for Administration

 Hereinafter referred to as “Institut Pasteur” 
 On one hand, 
 And 
 BLUEBIRDBIO INC., a company incorporated under the laws of Delaware, with offices at 840 Memorial Drive, Cambridge, MA 02139, United States, represented by Nick Leschly, Chief Executive Officer

 Hereinafter referred to as “Licensee”, 
 On the other hand, 
 Hereinafter mentioned as a Party or the Parties. 

Recitals 
 1. The Parties have signed a
license agreement on September 13, 2011 on a patented specific nucleotide sequence having a triplex structure, referred to as “DNA flap”, modified by an amendment n°1 dated April 27, 2012 (the “Agreement”).

 2. The Licensee has initiated a program to treat cancerous and/or pre-cancerous conditions by genetically modifying T cells to express
antigen binding domain(s) on their surface that target tumor associated antigen(s). 
 3. Institut Pasteur agrees to extend the Field as
follows, and the Parties agree to modify some definitions, according to the terms and conditions of this Amendment n°2. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 Now, therefore, the Parties hereby agree as follow: 

Article 1. Scope 
 The scope of this
Amendment n°2 is to extend the Field of the Agreement and the license granted by Institut Pasteur, and to make some modifications. 

Article 2. Modifications 
 2.1. The
following definitions shall replace the definitions of the Agreement: 
  

	 	•	 	 “Gene therapy” shall mean the use of a vector containing at least one DNA sequence that encodes at least one protein, in order to restore the
functional activity of one or more resident non-functional gene copies, or provide for the introduction and expression of novel protein(s) not normally expressed in the cell type or expression of protein(s) that do not exist normally in nature. The
introduced protein(s) are not intended to generate a prophylactic and/or therapeutic immune response against the protein encoded by the introduced DNA sequence of interest for use in Vaccination. 

 

	 	•	 	 “Ex vivo” shall mean that cells are extracted from a patient, corrected or otherwise modified by Gene Therapy, and transplanted or dosed back
into patient. 

  

	 	•	 	 “Vaccination” shall mean the use of a vector containing at least one DNA sequence that encodes at least one protein with the intent to
generate an immune response against the protein encoded by the DNA sequence of interest to cause a prophylactic or therapeutic effect in humans and other animals. The protein encoded by the DNA sequence of interest shall not restore an altered or
non existing protein function or, modify existing protein function. 

  

	 	•	 	 “Field” shall mean ex vivo Gene therapy for human disorders limited to adrenoleukodystophy (ALD) (including but not limited to AMN, CCALD,
and all other variants of this disease caused by genetic mutations), beta hemoglobinopathies (including but not limited to beta-thalassemia and sickle cell anemia), [***] leukemias, lymphomas, B-cell malignancies and solid tumors by producing
chimeric antigen receptor T-cells [***] for [***] and [***] the “Field” includes in vivo as well as ex vivo Gene therapy. [***] 

 2.2. The following sentence is hereby added to the end of Article 2.1 of the Agreement: “At Licensee’s request, the Parties agree to discuss in good faith about the [***].” 

2.3. The following sentence is hereby added to the end of Article 4.4 of the Agreement: “Further, Licensee shall have the right to seek patent term
extension according to the Drug Price Competition and Patent Term Restoration Act of 1984 (Hatch-Waxman) for any Patent based on Product(s) (in addition to an SPC(s) as provided in Article 4.4). Institut Pasteur will reasonably assist Licensee if
Licensee elects to initiate to obtain any such patent term extension”. 
 Article 3. Other Terms 

3.1. Upon signature of this Amendment 2 by the Parties, Licensee shall pay Institut Pasteur [***] exclusive of taxes. This amount cannot be set-off
against future royalties. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 Article 4. Miscellaneous 
 4.1. All the other provisions of the Agreement remain unchanged and fully applicable between the Parties. 
 4.2. This Amendment n°2 is effective from the date of signature by the Parties. 
 4.3. This
Amendment n°2 makes integral part of the Agreement. 
 IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed by their
authorized respective representative. 
 Made in Paris, 
 In duplicate. 
  

					
	 Date: 16 OCT. 2012
  

/s/ Christophe Mauriet
	 		 	 Date: 16 OCT. 2012
  

/s/ Nick Leschly

	 INSTITUT PASTEUR
 Christophe
Mauriet
 Senior Executive Vice-President
	 		 	 BLUEBIRDBIO INC.
 Nick
Leschly
 Chief Executive OfficerEX-10.9

 Exhibit 10.9 
 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND
EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. 
 LICENSE AGREEMENT 
 BETWEEN 

RESEARCH DEVELOPMENT FOUNDATION 
 AND 
 BLUEBIRD BIO, INC. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 TABLE OF CONTENTS 

 

			
	 	  	 Page

		
	 ARTICLE I Definitions
	  	1
		
	 ARTICLE II Grant of License
	  	3
	 Scope of License
	  	3
	 Right to Sublicense
	  	3
	 Retained Rights
	  	3
	 Government Rights
	  	3
		
	 ARTICLE III Patents
	  	4
	 Patent Applications
	  	4
	 Patent Prosecution and Maintenance
	  	4
	 Patent Costs
	  	4
		
	 ARTICLE IV Royalties and Other Consideration
	  	4
	 License Fee
	  	4
	 Royalty
	  	4
	 Basis of Royalty Obligation
	  	5
	 Limitation on Deductions from Royalty Payments
	  	5
	 Milestone Payments
	  	5
	 Marketing Arrangements
	  	5
		
	 ARTICLE V Reports and Payments
	  	5
	 Progress Reports
	  	5
	 Notice of Commercial Sale
	  	5
	 Royalty Reports and Payments
	  	6
	 U.S. Dollars
	  	6
	 Report on Termination
	  	6
	 Books and Records
	  	6
	 Delinquent Payments
	  	7
		
	 ARTICLE VI Diligence; Minimum Royalties
	  	7
		
	 ARTICLE VII Protection of Patents
	  	8
	 Protection
	  	8
	 Notice of Infringement; Licensor Enforcement of Third Party Infringement
	  	8
	 Notice of Infringement; Claim of Licensee Infringement
	  	8
	 Reasonable Assistance
	  	8
	 Declaratory Judgment Actions
	  	8
	 Patent Certifications
	  	8

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

			
	 ARTICLE VIII Disclaimer of Liability and/or Warranty
	  	8
	 No Warranty
	  	8
	 No Damages
	  	9
	 No Warranty of Quality or Usefulness
	  	9
	 Indemnification
	  	9
	 Insurance
	  	9
		
	 ARTICLE IX Term; Termination
	  	9
	 Term
	  	9
	 Termination for Cause; Insolvency
	  	10
	 Default
	  	10
	 Commercialization Rights Upon Termination
	  	10
	 Provisions Surviving Termination
	  	10
		
	 ARTICLE X Representations and Warranties
	  	11
	 Warranty to Title
	  	11
	 Power and Authority
	  	11
	 Compliance with Laws
	  	11
	 No Knowledge of Infringement
	  	11
		
	 ARTICLE XI Agency/Partnership/Use of Name
	  	11
	 No Agency
	  	11
	 No Partnership
	  	11
	 Prohibition Against Use of Name
	  	11
		
	 ARTICLE XII Marking
	  	12
		
	 ARTICLE XIII Nondisclosure of Confidential Information
	  	12
		
	 ARTICLE XIV Miscellaneous
	  	13
	 Captions
	  	13
	 Notices
	  	13
	 Assignment
	  	13
	 No Waiver
	  	13
	 Choice of Law and Jurisdiction
	  	14
	 Severability
	  	14
	 Further Acts
	  	14
	 Entire Agreement
	  	14
	 Successors and Assigns
	  	14
		
	 EXHIBIT 1
	  	
	 Licensed Patents
	  	
		
	 EXHIBIT 2
	  	
	 Milestone Payments
	  	

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 LICENSE AGREEMENT 

This License Agreement (hereinafter referred to as “Agreement”) is made and entered into as of the 7th day of December, 2011
(the “Effective Date” of this Agreement), by and between RESEARCH DEVELOPMENT FOUNDATION (hereinafter referred to as “Licensor”), a Nevada nonprofit corporation having its office at 402 North Division Street, Carson City, Nevada,
89703; 
 AND 

BLUEBIRD BIO, INC., having an office at 840 Memorial Drive, Cambridge, Massachusetts, 02139 (hereinafter referred to as “Licensee”).

 WITNESSETH: 
 WHEREAS, Licensor is a nonprofit organization exempt from taxation under Section 501(c)(3) of the Internal Revenue Code of 1986; 

WHEREAS, Licensor is the owner of “Licensed Patents” (as defined below); 

WHEREAS, Licensor has determined that the grant of a license to Licensee is the only practicable manner in which the Licensed Patents can
be utilized to benefit the public; 
 WHEREAS, Licensee desires to obtain a world-wide license from Licensor as described
herein, and Licensor desires to grant such a license pursuant to the terms and conditions of this Agreement; 
 NOW, THEREFORE,
in consideration of the above premises and the covenants herein, the parties agree as follows: 
 ARTICLE I 

Definitions 
 As used in this Agreement, the following capitalized terms shall have the following respective meanings: 
 1.1 The term “Licensed Patents” shall mean the United States and foreign patent applications and issued patents listed in Exhibit 1, including all continuations, continuations-in-part,
divisionals, patents of addition, reissues, renewals or extensions (including supplementary protection certificates) and all foreign counterparts of the foregoing. 
 1.2 The term “Licensed Product” shall mean any process, method, material, composition, drug, or other product or portion of a product within a Valid Claim of the Licensed Patents. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 1.3 The term “Make, Use or Sell” shall mean to develop, have developed,
produce, have produced, make, have made, manufacture, have manufactured, use, have used, offer for sale, have offered for sale, sell, have sold, rent, have rented, lease, have leased, import or have imported a Licensed Product. 

1.4 The term “Affiliate” shall mean any present or future companies, corporations, partnerships, joint ventures, business
trusts or other business entities organized under the laws of any nation (a) with respect to which: (i) at least fifty percent (50%) in value of the total equity interests, (ii) at least fifty percent (50%) of the total
combined voting power of all classes of shares entitled to vote, or (iii) at least fifty percent (50%) of the profits interest in the case of a partnership, joint venture or other non-stock entity, is directly or indirectly under the
control of Licensee, or (b) with respect to which Licensee has effective control, directly or indirectly. “Control” shall mean the possession of the power to direct or cause the direction of the management and the policies of an
entity, whether through an ownership interest or by contract or otherwise. The term “Licensee” wherever used herein shall include any Affiliate of Licensee. 
 1.5 The term “Net Sales” shall mean the gross amount received with respect to the sale or other transfer of Licensed Product, less the following deductions for amounts actually incurred related
to such sale or other transfer and included in the gross invoiced amount: (a) normal, customary trade discounts (including volume discounts), credits and rebates, and allowances and adjustments for rejections, recalls, returns or retroactive
price reductions; and (b) freight, insurance, sales, use, excise, value-added and similar taxes or duties imposed on the sale. 
 No other allowance or deduction shall be made by whatever name known. For the avoidance of doubt, transfers of a Licensed Product between any of Licensee, an Affiliate or a sublicensee for sale by the
transferee shall not be considered Net Sales hereunder. 
 1.6 The terms “commercialize” and
“commercialization” shall mean the Making, Using, or Selling, licensing or other use by Licensee (or a sublicensee) of the Licensed Product under such circumstances as may be permitted by applicable international, federal, and state laws
and regulation. 
 1.7 The term “Valid Claim” shall mean, in the country of manufacture or sale, (a) a claim of
any issued and unexpired patent within the Licensed Patents that (i) has not been permanently revoked, nor held unenforceable, unpatentable or invalid by a decision of a court or other governmental agency of competent jurisdiction that is
unappealable or unappealed in the time allowed for appeal, (ii) has not been admitted to be invalid or unenforceable through reissue or disclaimer or otherwise, and (iii) has not been lost through an interference, reexamination, post-grant
review or reissue proceeding; or (b) a pending claim of a pending patent application included in the Licensed Patents that was filed and has been prosecuted in good faith and has not been (i) cancelled, withdrawn, abandoned or finally
disallowed without the possibility of appeal or refiling of such application, or (ii) pending for more than [***] since such claim was first presented; provided, however, that such claim pending for more than [***] shall be a Valid Claim if and
when it is issued as a claim of an issued and unexpired patent included within Licensed Patents, or if it is part of an opposition, interference, re-examination or other such administrative proceeding. 

1.8 The term “Cover(s)” or “Covered” or “Covering” shall mean that a product, process, material,
composition, drag, or other product or portion of a product would infringe a Valid Claim in a Licensed Patent (or in the case of a Valid Claim in a patent application within the Licensed Patents, would infringe such Valid Claim if it were in an
issued patent) but for the exclusive license granted to Licensee hereunder. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 ARTICLE II 
 Grant of License 
 2.1 Scope of License. Licensor hereby grants and
Licensee hereby accepts a worldwide, exclusive license under the Licensed Patents to Make, Use or Sell Licensed Products. Except as provided herein, no other, further, or different license is hereby granted, either expressly or by implication.

 2.2 Right to Sublicense. Licensor hereby grants and Licensee hereby accepts the right to grant sublicenses through
multiple tiers to third parties to all or any portion of Licensee’s rights hereunder. Licensee shall, within thirty (30) days of the grant of each such sublicense, give written notice of such sublicenses to Licensor and provide Licensor
with a copy thereof; provided that Licensee may redact those portions of such sublicenses that are not necessary for Licensor to determine whether Licensee is in compliance with its obligations under this Agreement. Licensee shall incorporate terms
and conditions into its sublicense agreements sufficient to enable Licensee to comply with this Agreement. Upon termination of this Agreement for any reason, Licensor shall grant to a sublicensee that is not in material breach of its sublicense a
direct license granting rights and terms equivalent to the sublicense rights and terms which Licensee previously granted to such sublicensee, provided that Licensor shall have no greater rights and obligations to any such sublicensee than Licensor
has to Licensee under this Agreement. 
 2.3 Retained Rights. Licensor retains the right, on behalf of itself and other
nonprofit academic research institutions, to practice and use the Licensed Patents for any academic, non-clinical research and educational purposes. Licensee agrees that, notwithstanding any other provision of this Agreement, it has no right to
enforce the Licensed Patents against any such practice or use by any such institution. 
 2.4 Government Rights. If any
invention described and claimed in the Licensed Patents is developed with the support of federal research funds, Title 35, Sections 200-212 of the United States Code (the “Bayh-Dole Act”) shall apply. Among other things, the provisions of
the Bayh-Dole Act provide the United States Government with non-exclusive rights in any inventions arising from the use of federal funds and also generally impose the obligation that any products embodying the subject invention or produced through
the use of such invention be manufactured substantially in the United States. If and to the extent the Bayh-Dole Act is 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 
applicable to any Licensed Patents, Licensee acknowledges and agrees that the rights granted under this Agreement are subject to the applicable terms and conditions of the Bayh-Dole Act and that
Licensee will ensure that all relevant obligations under the Bayh-Dole Act provisions are met. 
 ARTICLE III 

Patents 

3.1 Patent Applications. Licensor represents that it has timely filed patent applications relating to the Licensed Patents in the
countries listed on Exhibit 1 hereto. 
 3.2 Patent Prosecution and Maintenance. Licensor will control the conduct,
preparation, filing and prosecution of such patent applications within the Licensed Patents and will maintain any patents issued thereon, but will provide Licensee with copies of all office actions and responses thereto and will consider and take
into account in good faith Licensee’s comments with respect thereto. Notwithstanding the foregoing sentence, in the event that Licensor within its sole judgment and discretion determines that prosecution or maintenance of a patent in a
particular country is not economically viable or otherwise feasible, Licensor shall promptly notify Licensee of Licensor’s intention to abandon such patent application or patent. Upon receipt of such notice, Licensee, in its sole discretion,
may elect to assume responsibility (and to pay associated fees and expenses) with respect to a patent application or patent which Licensor intends to abandon. Licensee may, in its sole discretion, abandon any patent application or patent for which
it has previously assumed responsibility and will not be liable to Licensor in any way for such abandonment. 
 3.3 Patent
Costs. Licensee shall reimburse Licensor for [***] for filing, prosecuting and maintaining the Licensed Patents. Licensor shall invoice Licensee for such patent costs quarterly, and undisputed payments shall be made by Licensee within thirty
(30) days after receipt of each invoice. 
 ARTICLE IV 

Royalties and Other Consideration 
 4.1 License Fee. Licensee shall pay Licensor an up-front non-refundable license fee of [***] within ten (10) business days after the execution of this Agreement by the parties. 

4.2 Royalty. Licensee shall pay Licensor an earned royalty of [***] on Net Sales of Licensed Product, on a Licensed
Product-by-Licensed Product and country-by-country basis, where there is at least one Valid Claim of a Licensed Patent Covering such Licensed Product in such country at the time of first marketing approval. Such royalty shall continue until the
longer of: (a) expiry or end of the last Valid Claim within a Licensed Patent that Covers a Licensed Product in such country, or (b) ten (10) years from the first marketing approval; provided that the royalty shall be reduced by [***]
if payable under this clause (b) after the last Valid Claim 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 
expires or ends during such ten (10) year period. For clarity, no royalty shall be owed on any Licensed Product not Covered by a Valid Claim under a Licensed Patent at the time of first
marketing approval in the country in question, and further, under no circumstances shall any royalty be owed (during the term of this Agreement or thereafter) if all the Valid Claim(s) that Cover a Licensed Product in a country are held not valid,
unenforceable or otherwise unpatentable. For clarity, in such event, royalties already paid by Licensee shall not be refunded by Licensor. Only one (1) royalty shall be payable on a Licensed Product, regardless of the number of Valid Claims or
the number of patent applications and patents within the Licensed Patents under which such Licensed Product has been Made, Used or Sold. 
 4.3 Basis of Royalty Obligation. Royalty payments to be paid at the applicable rate(s) hereunder shall be paid on a Licensed Product by Licensed Product and country-by-country basis. 

4.4 Limitation on Deductions from Royalty Payments. Wherever this Agreement provides that Licensee may deduct expenses, payments
or other amounts from royalties payable to Licensor, such deduction shall be prorated over such time as is necessary to assure that the royalties payable to Licensor in any period shall not be reduced by more than [***]. 

4.5 Milestone Payments. In addition to the up-front license fee and royalties required under this Article IV, Licensee shall make
milestone payments to Licensor as set forth in Exhibit 2 hereto. Such cash payments shall be delivered to Licensor within forty-five (45) days after the end of the calendar quarter in which each of the milestone payment events indicated on such
exhibit occurs. 
 4.6 Marketing Arrangements. Where Licensed Products are sold by a third party other than Licensee or
sublicensee under any type of commercial arrangement between Licensee (or sublicensee) and such third party (including, without limitation, a joint venture, distributorship, or collaboration agreement), Net Sales for earned royalty purposes shall be
calculated based on the gross sales of Licensed Products by such third party. 
 ARTICLE V 

Reports and Payments 
 5.1 Progress Reports. Licensee agrees to make an annual report to Licensor each March covering Licensee’s (and its sublicensees’, if applicable) progress during the previous calendar year
toward research, development, commercialization and out-licensing of Licensed Products. Email communication shall suffice for the purpose of this reporting requirement. 
 5.2 Notice of Commercial Sale. Licensee shall notify Licensor, in writing, within thirty (30) days of the date of the first commercial sale of a Licensed Product to a third party by Licensee
or a sublicensee. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 5.3 Royalty Reports and Payments. Licensee agrees that Licensor shall, if
applicable, receive within forty-five (45) days after the end of each quarter of each calendar year: 
  

	 	(a)	a complete and accurate royalty report showing the information and basis on which such amounts have been calculated, including disclosure of at least the following
information: 

  

	 	i.	[***]; 

  

	 	ii.	[***]; 

  

	 	iii.	[***]; 

  

	 	iv.	[***]; and 

  

	 	(b)	payment of amounts due to Licensor pursuant to this Agreement, including, but not limited to, amounts pursuant to Articles IV and VI. 

5.4 U.S. Dollars. All amounts payable by Licensee shall be paid in U.S. Dollars. Conversion from currencies other than U.S.
Dollars shall be at the rate of exchange used by Licensee for its general accounting purposes, consistent with generally accepted accounting principles. 
 5.5 Report on Termination. Licensee also agrees to make a written report to Licensor within ninety (90) days after the expiration or termination of this Agreement, stating in such report the
amounts payable hereunder and the basis therefor not previously reported to Licensor. In the event of a termination prior to expiration of the Term, Licensee shall also continue to make annual reports pursuant to the provisions of this Agreement
covering sales, uses, or production and the applicable earned royalties and other amounts payable hereunder for Licensed Products made during the Term, but not used or sold until after termination thereof, until such time as all such makings, uses
or sales shall have terminated. Concurrent with the submittal of such post-expiration or post-termination report, Licensee shall pay Licensor all applicable royalties and other amounts payable hereunder. 

5.6 Books and Records. Licensee shall keep full, true, clear and accurate records and books of account with respect to the
Licensed Products subject to royalty or other payments hereunder. Said records and books of account shall be kept by Licensee at the usual places where its like records and books are kept and shall be retained for a period of three (3) years
following the end of the calendar year to which they pertain. Licensor shall have the right through an independent public accountant selected by Licensor and reasonably acceptable to Licensee to examine and inspect during normal business hours all
such records and books of account and such other records and accounts as may under recognized accounting practices contain information reasonably bearing upon the amounts payable to it under this Agreement. Prompt adjustment shall be made by the
proper party to compensate for any errors or omissions disclosed by such examination or inspection. In the event the examination or inspection results 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 
in a discrepancy in the correctness of the payments due under this Agreement in an amount in excess of [***] of the payments due Licensor for any single quarter audited, Licensee shall reimburse
Licensor for all reasonable out-of-pocket costs and fees associated with such examination or inspection, and all reasonable out-of-pocket costs and expenses required to collect the amount underpaid, including (but not limited to) reasonable
attorneys’ fees incurred in connection therewith. Neither such right to examine and inspect nor the right to receive such adjustment shall be affected by any statement to the contrary appearing on checks or otherwise, unless such statements
appear in a letter, signed by the party having such right and delivered to the other party, expressly waiving such right. Notwithstanding the foregoing, Licensor may require Licensee to furnish any other information reasonably requested to enable
Licensor to evaluate Licensee’s performance in accordance with this Agreement. 
 5.7 Delinquent Payments. Payments
provided for in this Agreement shall, when overdue, bear interest [***] per annum until paid, but in no event shall such interest exceed the usury limit, if any, as may exist from time to time in the State of Nevada. Each such payment when made
shall be accompanied by all interest so accrued. Said interest and the payment and acceptance thereof shall not negate or waive the right of Licensor to seek any other remedy, legal or equitable, to which it may be entitled because of the
delinquency of any payment or any other breach of this Agreement by Licensee. 
 ARTICLE VI 

Diligence; Minimum Royalties 
 Licensee shall undertake to use commercially reasonable and diligent efforts for a company of Licensee’s size and resources, directly or through a sublicensee, to develop or commercialize one or more
Licensed Products, including its first Licensed Product by 2016 and a second Licensed Product by 2018. Licensee will be considered not to have utilized reasonable commercial efforts unless it (or a sublicensee) makes the following minimum annual
royalty payments to Licensor: 
  

	 	(a)	[***]; 

  

	 	(b)	[***]; and 

  

	 	(c)	[***]. 

 Such payments will be creditable
against earned royalties otherwise due to Licensor for a given calendar year. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 ARTICLE VII 
 Protection of Patents 
 7.1 Protection. Each party agrees to
cooperate fully in any action under this Article VII which is controlled by the other party, including by joining as a party to any proceeding if required by applicable law; provided that the controlling party reimburses the cooperating party
promptly for any reasonable costs and expenses incurred by the cooperating party in connection with providing such assistance. [***] 
 7.2 Notice of Infringement; Licensor Enforcement of Third Party Infringement. Licensor and Licensee shall each give prompt written notice to the other of any infringement of a Licensed Patent by
any third party as may come to its knowledge. [***] 
 7.3 Notice of Infringement; Claim of Licensee Infringement.
Licensee shall promptly advise Licensor in writing of any notice or claim of any infringement and of the commencement against it of any suit or action for infringement of a third party patent made or brought against Licensee and based upon the use
hereunder by Licensee of the Licensed Patents. [***] 
  

	 	(a)	[***] 

  

	 	(b)	[***] 

 7.4 Reasonable
Assistance. [***] 
 7.5 Declaratory Judgment Actions. If a declaratory judgment action is brought naming Licensor or
Licensee or any of its Affiliates or sublicensees as a defendant and alleging invalidity, unenforceability or non-infringement of any Licensed Patents, Licensee or Licensor, as the case may be, shall promptly notify the other party in writing. [***]

 7.6 Patent Certifications. Each party shall notify and provide the other with copies of any allegations of alleged
patent invalidity, unenforceability or non-infringement of a Licensed Patent pursuant to the FDA’s Paragraph IV Patent Certification procedure by a third party filing an Abbreviated New Drug Application, an application under §505(b)(2) of
the Federal Food, Drug and Cosmetics Act, or any other similar patent certification by a third party, and any foreign equivalent thereof. Such notification and copies shall be provided to the other party within five (5) business days after the
party receives such certification. 
 ARTICLE VIII 
 Disclaimer of Liability and/or Warranty 
 8.1 No Warranty. Nothing
in this Agreement shall be construed as: 
  

	 	(a)	a warranty or representation by Licensor as to the validity or scope of any Licensed Patents; or 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

	 	(b)	a warranty or representation that anything Made, Used or Sold under any license granted in this Agreement is or will be free from infringement of patents, copyrights,
and/or trademarks of third parties; or 

  

	 	(c)	an express or implied warranty of merchantability or fitness for a particular purpose. 

8.2 No Damages. Neither party shall be liable to the other party for indirect, special, consequential or punitive damages under
any circumstances. 
 8.3 No Warranty of Quality or Usefulness. Licensor shall have no responsibility for the ability of
Licensee to use such information, the quality or performance of any process or any Licensed Product produced by Licensee with the aid of such information, or with respect to claims of third parties arising from Licensee’s use of such
information. 
 8.4 Indemnification. Licensee shall assume all responsibility and liability for the sale, use,
production, and/or commercialization of the Licensed Products, including, but not limited to, the safety, effectiveness, and reliability of the Licensed Products produced pursuant to this Agreement. Licensee further agrees to defend, indemnify, and
hold harmless Licensor, its trustees, directors, officers, employees, agents, representatives, successors, assigns, affiliated entities and Other Corporations (as defined in Section 11.3 below) (collectively “Indemnitees’’) from
and against any and all liability, demands, damages, expenses and losses for death, personal injury, illness, or property damage, including the cost of defense against same, which may be asserted by third parties, or any third party claims which may
arise from the sale, use, production, commercialization, or other disposition of Licensed Products pursuant to any right or license granted under this Agreement, except to the extent that such liability, demands, damages, expenses or losses relate
to or arise out of Licensor’s material breach of its representations, warranties and covenants under this Agreement, or Licensor’s or Indemnitees’ gross negligence or willful misconduct. 

8.5 Insurance. Licensee agrees to purchase and/or maintain insurance coverage sufficient, taking into account its other assets, to
establish the ability of Licensee to honor the indemnity made herein, and Licensor shall be listed as an additional named insured on any such insurance coverage. Licensee shall furnish evidence satisfactory to Licensor of its insurance coverage upon
request of Licensor. Upon Licensee’s, or any of its sublicensees’, Making, Use or Sale of Licensed Products commercially, the initial amount of insurance coverage required is in the face amount of [***]. 

ARTICLE IX 

Term; Termination 
 9.1 Term. The Term of this Agreement (“Term”) shall continue until its expiration upon the later of: (a) there being no more Valid Claims within the Licensed Patents, or (b) the
expiration of Licensee’s royalty obligations on Licensed Products that are subject to an earned royalty, if such earned royalty is based on the minimum ten (10) year royalty period described in Section 4.2(b) above; unless this
Agreement is earlier terminated as herein provided. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 9.2 Termination for Cause; Insolvency. If Licensee shall determine that it
intends to file for bankruptcy or reorganization, it shall give prompt written notice to Licensor. Failure to give such notice shall cause immediate termination of this Agreement, and all rights of Licensee in the Licensed Patents shall
automatically revert to Licensor. If Licensee shall become bankrupt; if the business or any assets or property of Licensee shall be placed in the hands of a receiver, assignee or trustee, whether by the voluntary act of Licensee or otherwise; if
Licensee institutes or suffers to be instituted any procedure in bankruptcy court for reorganization or rearrangement of its financial affairs; if Licensee makes a general assignment for the benefit of creditors; or if Licensee or an Affiliate or a
sublicensee (with the assistance, consent, approval or cooperation of Licensee) institutes or suffers to be instituted any procedure, administratively or in a court, challenging validity or patentability of any patent or patent application within
the Licensed Patents, this Agreement shall immediately terminate, and all rights of Licensee in the Licensed Patents shall automatically revert to Licensor. Upon occurrence of any of the foregoing events, Licensee shall give prompt written notice
thereof to Licensor. 
 9.3 Default. Upon any breach or default under this Agreement by Licensee, Licensor may give
written notice thereof to Licensee, and Licensee shall have ninety (90) days thereafter to cure such breach or default, except in the event of a breach or default by non-payment, in which case the cure period shall be thirty (30) days. If
such breach or default is not cured within such period, Licensor shall have the right in its sole option to cancel and terminate this Agreement and the licenses granted by it by giving written notice thereof to Licensee. In such event, Licensor may
also seek such other relief as may be provided by law or in equity in such circumstances. 
 9.4 Commercialization Rights
Upon Termination. Upon termination hereof under Section 9.2 or 9.3, all rights of Licensee in the Licensed Patents shall revert to Licensor, and Licensee agrees to execute appropriate written releases and/or assignments of such rights to
Licensor; and further, Licensee agrees to discontinue the commercialization of the Licensed Patents. Upon expiration of the Term and Licensee’s payment of all amounts due Licensor hereunder, Licensee will continue to have commercialization
rights with respect to the Licensed Products with no further royalty obligation to Licensor, and Licensor will not license or otherwise grant rights to any third party inconsistent with such rights remaining exclusively in Licensee. 

9.5 Provisions Surviving Termination. Articles X and XIII and Sections 8.1, 8.2, 8.3, 8.4, 9.4 and 11.3 of this Agreement shall
survive expiration or termination of this Agreement. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 ARTICLE X 
 Representations and Warranties 
 10.1 Warranty to Title. Licensor
represents and warrants that it owns the Licensed Patents and has the legal power and authority to extend the rights granted to Licensee pursuant to this Agreement, and that it has not assigned, licensed, pledged or compromised the Licensed Patents
or made any commitments or offers inconsistent with or in derogation of the rights created by this Agreement. 
 10.2 Power
and Authority. Licensee represents and warrants that (a) it has full power and authority to enter into this Agreement and to carry out the transactions contemplated hereby; and (b) this Agreement constitutes the legal, valid and
binding obligation of Licensee, enforceable against Licensee in accordance with its terms. 
 10.3 Compliance with Laws.
Licensee represents and warrants that it will comply with all applicable laws and regulations, including without limitation, all United States laws and regulations controlling the export of commodities and technical data. Licensee will be solely
responsible for any violation of such laws or regulations by Licensee, and it will defend and hold Licensor harmless in the event of any legal action of any nature occasioned by such violation. 

10.4 No Knowledge of Infringement. Licensor represents that it has no knowledge of any infringement of the Licensed Patents by any
third party. 
 ARTICLE XI 
 Agency/Partnership/Use of Name 
 11.1 No Agency. Neither party shall
be deemed to be an agent of the other party as a result of any transaction under or related to this Agreement, and shall not in any way pledge the other party’s credit or incur any obligations on behalf of the other party. 

11.2 No Partnership. This Agreement shall not constitute either a partnership or a joint venture, and neither party may be bound
by the other to any contract, arrangement or understanding except as specifically stated herein. 
 11.3 Prohibition Against
Use of Name. Except to the extent required to comply with applicable laws and regulations, without prior written consent obtained from Licensor, Licensee (including any Affiliate or sublicensee of Licensee) shall not use for purposes of sales,
advertising, marketing, marking of goods, promotion to investors, press releases or other publicity, etc.: (i) the name of (or any other information which would identify) Licensor or any corporation which is controlled by the same persons who
control Licensor (“Other Corporation”); (ii) the names of trustees, directors, officers, or employees of Licensor or an Other Corporation; or (iii) any trademarks (or adaptations thereof) of Licensor or an Other Corporation. The
foregoing notwithstanding, without the consent of Licensor, Licensee may 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 
indicate other than in advertising that it is licensed by Licensor under the Licensed Patents and identify the inventors, their affiliation with Licensor, and their relationship to Licensor, and
further, Licensee may comply with disclosure requirements of all applicable laws relating to its business, including, without limitation, United States and state securities laws. 

ARTICLE XII 

Marking 

To the extent commercially feasible and consistent with prevailing business practices, Licensee agrees to apply or have applied to all
articles and to all containers containing Licensed Products manufactured by it or any sublicensee(s) under this Agreement the number of each issued patent under the Patent Rights that applies to such Licensed Product. 

ARTICLE XIII 

Nondisclosure of Confidential Information 
 All confidential or proprietary business, scientific and technical information communicated by one party to the other party under this Agreement, including information contained in unpublished patent
applications, shall be kept confidential by such other party. Notwithstanding the foregoing, either party shall be relieved of the confidentiality obligations herein and not be prevented by this Agreement from utilizing any information received by
it from the other party if: 
  

	 	(a)	the information, at the time of disclosure, is in the public domain or, after disclosure, becomes part of the public domain through no act or omission of the receiving
party; 

  

	 	(b)	the receiving party can show that the information was in its possession at the time of disclosure and was not acquired, directly or indirectly, from the disclosing
party; 

  

	 	(c)	the information is lawfully obtained or received on a non-confidential basis from a third party, other than the disclosing party, having the legal right to transmit
same; or 

  

	 	(d)	the disclosure of such information is essential for the commercial exploitation of the Licensed Patents under this Agreement, provided that such information is
disclosed subject to a secrecy agreement. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 ARTICLE XIV 
 Miscellaneous 
 14.1 Captions. The captions herein are for
convenience only and shall not be deemed to limit or otherwise affect the construction hereof. 
 14.2 Notices. Any
notice or other communication hereunder must be given in writing and (a) delivered in person, (b) transmitted by telefax or other telecommunications mechanism, (c) mailed by certified or registered mail, postage prepaid, receipt
requested, or (d) sent by overnight delivery with charges prepaid and receipt acknowledged, as follows: 
 If to Licensor,
addressed to: 
 Research Development Foundation 
 402 North Division Street 
 Carson City, Nevada 89703 

   Attn:  Andrew MacKenzie, Esq. 
 Phone:  (775) 882-0202 
 Fax:  (775) 882-7918

 If to Licensee, addressed to: 
 bluebird bio, inc. 
 840 Memorial Drive 

Cambridge, Massachusetts 02139 
    Attn:  Head of Business Development 

Phone:  (617) 873-0900 
 Fax:  (617) 576-2421 
 or to such other address or to such other
person as the party shall have last designated by such notice to the other party. Each such notice or other communication shall be effective when actually received at such address. 

14.3 Assignment. This Agreement, in whole or in part, shall not be assignable by either party without prior written consent of the
other party (unless to a successor entity to such party by merger, acquisition, consolidation or other non-bankruptcy reorganization or sale of substantially all of its assets or that portion of its business to which this Agreement relates), and any
attempted assignment without such consent shall be void. 
 14.4 No Waiver. The failure of either party to enforce at any
time any of the provisions of this Agreement, or any rights in respect thereto, or to exercise any election herein provided, shall in no way be considered to be a waiver of such provisions, rights, or elections, or in any way to affect the validity
of this Agreement. The exercise by either party of any of its rights herein or any of its elections under the terms or covenants herein shall not preclude either party from exercising the same or any other rights it may have under this Agreement,
irrespective of any previous action or proceeding taken by either party hereunder. 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 14.5 Choice of Law and Jurisdiction. This Agreement shall be governed and
construed in accordance with the laws of the State of Nevada, U.S.A. applicable to contracts made in such State without regard to conflicts of law doctrines, and the parties agree that jurisdiction and venue for any dispute regarding this Agreement
will be in such State. 
 14.6 Severability. If any provision of this Agreement is judicially determined to be void or
unenforceable, such provision shall be construed to be severable from the other provisions of this Agreement, which shall retain full force and effect. 
 14.7 Further Acts. The parties hereto agree promptly to execute, forward, or otherwise provide all documents and material necessary or desirable to effectuate this Agreement. 

14.8 Entire Agreement. This Agreement constitutes the entire agreement between the parties with respect to the subject matter
hereof and shall supersede all previous communications, either oral or written, between the parties hereto with respect to the subject matter hereof. No agreement or understanding bearing on the same shall be binding upon either party hereto unless
it shall be in writing and signed by the duly authorized officer or representative of each of the parties and shall expressly refer to this Agreement. 
 14.9 Successors and Assigns. This Agreement shall be binding on and shall inure to the benefit of the parties hereto, and their respective successors and assigns. 

IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed in multiple originals by their duly authorized
representatives. 
  

			
	RESEARCH DEVELOPMENT FOUNDATION
		
	By:	 	 /s/ Andrew MacKenzie

		
	Print Name:	 	 Andrew MacKenzie

		
	Title:	 	 Vice President

	
	BLUEBIRD BIO, INC.
		
	By:	 	 /s/ Nick Leschly

		
	Print Name:	 	 Nick Leschly

		
	Title:	 	 CEO

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 EXHIBIT 1 
 Licensed Patents 
 [See attached insert from F&J Master Listings] 

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

			
	

	  	Research Development Foundation by Alias
	  	  
 Master Listing of
Technologies

	  	  
 10/04/2011

  

			
	CLFR: 010	  	 TITLE: [***]
 Summary:
[***]

 Client Reference No.: NULL 
 [***] 
  

													
	 Country
	  	 Case
	  	 Status
	  	 Application No.
	  	 Filing Date
	  	 Patent No.
	  	 Granted

	 [***]
	  		  		  		  		  		  	

  

			
	CLFR: 011	  	 TITLE: [***]
 Summary:
[***]

 Client Reference No.: CLFR:011 
 [***] 
  

													
	 Country
	  	 Case
	  	 Status
	  	 Application No.
	  	 Filing Date
	  	 Patent No.
	  	 Granted

	 [***]
	  		  		  		  		  		  	

  

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

			
	

	  	Research Development Foundation by Alias
	  	  
 Master Listing of
Technologies

	  	  
 10/04/2011

  

			
	CLFR: 014	  	 TITLE: [***]
 Summary:
[***]

 Client Reference No.: NULL 
 [***] 
  

													
	 Country
	  	 Case
	  	 Status
	  	 Application No.
	  	 Filing Date
	  	 Patent No.
	  	 Granted

	 [***]
	  		  		  		  		  		  	

  

 CERTAIN CONFIDENTIAL PORTIONS OF THIS EXHIBIT WERE OMITTED AND REPLACED WITH “[***]”. A
COMPLETE VERSION OF THIS EXHIBIT HAS BEEN FILED SEPARATELY WITH THE SECRETARY OF THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO AN APPLICATION REQUESTING CONFIDENTIAL TREATMENT PURSUANT TO RULE 406 PROMULGATED UNDER THE SECURITIES ACT OF 1933,
AS AMENDED. 
  

 EXHIBIT 2 
 Milestone Payments 
 Except as provided herein, milestone payments in the
following amounts shall be paid for each Licensed Product requiring marketing approval, payable on a product-by-product basis: 

[***] 
 Each
milestone shall be payable one time only, on a Licensed Product-by-Licensed Product basis. 
 In the event that a Licensed
Product achieves the milestone on more than one occasion, only the first achievement of such shall be subject to milestone consideration. For example, [***].

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00217-of-00352.parquet"}]]